Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-03-01
2000-09-26
Ramsuer, Robert W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514405, 5483605, A61K 3800, A61K 31415, C07D23154
Patent
active
061242640
ABSTRACT:
##STR1## This invention is directed to compounds of formula (I) and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretagogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGR-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula (I).
REFERENCES:
Tetrahedron, vol. 50, No. 2, 1994, pp. 515-528, Moreno-Manas et al.
Hormone Research, Thord Resen, et al., 1995, vol. 43, pp. 93-99.
Eur. Journal of Endocrinology, Marie Degerhblad et al, 1995, 133:180-8.
Eur. Journal of Endocrinology, Jens Ol Jorgensen et al, 1994, 130:224-8.
Journal of Clinical Endocrinology and Metabolism, K. C. Copeland et al, 1994, vol. 78, pp. 1040-1047.
Journal of Clinical Endocrinilogy and Metabolism, Joseph A. Aloi et al, 1994, vol. 79, pp. 943-949.
The New England Journal of Medicine, Evan Loh et al, 1996, vol. 334, No. 13, pp. 856-857.
The New England Journal of Medicine, Serafino Fazio et al, vol. 334, No. 13, 1996, pp. 809-814.
Circulation, Antonio Cittadini et al, vol. 93, No. 4, Feb. 15, 1996, pp. 800-808.
Circulation, Renhui Yang et al, vol. 92, No. 2, Jul. 15, 1995, pp. 262-267.
The Martindale The Extra Pharma Copia 30a. Ed. The Parm Press, Londres, 1993, pp. 655-657.
Carpino Philip A
DaSilva-Jardine Paul A
Lefker Bruce A
Ragan John A
Benson Gregg C.
Pfizer Inc.
Ramsuer Robert W.
Richardson Peter C.
Ronau Robert T.
LandOfFree
Heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100208